(P-588) Improved Lipid Profile in Virologically Suppressed People with HIV-1 Switching to Tenofovir DF-Containing, Ainuovirine-Based Compared to Tenofovir Alafenamide-Containing, Boosted Elvitegravir-Based Antiretroviral Regimen: the Secondary Analyses of 48-Week Results of the SPRINT Trial, a Randomized, Active-Controlled Phase 3 Study

Thursday, October 17, 2024

12:15 PM – 1:30 PM US PT

Location: Halls JK

Co-Author(s)

HW

Hao Wu, M.D.

Beijing Youan Hospital Affiliated to Capital Medical University
Beijing, Beijing, China
pm

ping ma, n/a

Nankai University Second People's Hospital, School of Medicine, Nankai University
tianjin, Tianjin, China
QZ

Qingxia Zhao, M.D.

Zhengzhou Municipal Sixth People’s Hospital and Infectious Disease Hospital of Henan Province
Zhengzhou, Henan, China
hw

hongxia wei, n/a

The Second Hospital of Nanjing, Nanjing University of Chinese Medicine
Nanjing, Jiangsu, China
HL

Hongzhou Lu, M.D.

Shenzhen Municipal Third Hospital
Shenzhen, Guangdong, China
HW

Hui Wang, M.D.

Shenzhen Municipal Third Hospital
Shenzhen, Guangdong, China
SH

Shenghua He, M.D.

Chengdu Municipal Public Health Clinical Center
Chengdu, Sichuan, China
ZC

Zhu Chen, M.D.

Chengdu Municipal Public Health Clinical Center
Chengdu, Sichuan, China
yaokai Chen, Doctoral Degree

Director
Chongqing Public Health Medical Center
chongqing, Chongqing, China
Mw

Ming wang, n/a

The First Hospital of Changsha
Changsha, Hunan, China
WC

Weiping Cai, M.D.

Guangzhou Municipal Eighth People’s Hospital Affiliated to Guangzhou Medical University
Guangzhou, Guangdong, China

Hong Qin, MD, PhD

Cheif Medical Officer
Jiangsu Aidea Pharmaceutical Co., Ltd
Yangzhou, Jiangsu, China (People's Republic)